120 related articles for article (PubMed ID: 9685244)
21. Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.
Zapico JM; Serra P; García-Sanmartín J; Filipiak K; Carbajo RJ; Schott AK; Pineda-Lucena A; Martínez A; Martín-Santamaría S; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2011 Jun; 9(12):4587-99. PubMed ID: 21552627
[TBL] [Abstract][Full Text] [Related]
22. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
23. [Design, synthesis and evaluation of malonic acid-based PTP1B inhibitors].
Du X; Zhang SE; Liu JZ; Nie FL; Ye F; Tian JY; Xiao ZY
Yao Xue Xue Bao; 2012 Mar; 47(3):367-73. PubMed ID: 22645761
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
[TBL] [Abstract][Full Text] [Related]
25. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
26. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.
Zhang X; Gonnella NC; Koehn J; Pathak N; Ganu V; Melton R; Parker D; Hu SI; Nam KY
J Mol Biol; 2000 Aug; 301(2):513-24. PubMed ID: 10926524
[TBL] [Abstract][Full Text] [Related]
27. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.
Blagg JA; Noe MC; Wolf-Gouveia LA; Reiter LA; Laird ER; Chang SP; Danley DE; Downs JT; Elliott NC; Eskra JD; Griffiths RJ; Hardink JR; Haugeto AI; Jones CS; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robinson RP; Subramanyam C; Vaughn-Bowser ML; Yocum SA
Bioorg Med Chem Lett; 2005 Apr; 15(7):1807-10. PubMed ID: 15780611
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
30. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
31. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
Matter H; Schwab W; Barbier D; Billen G; Haase B; Neises B; Schudok M; Thorwart W; Schreuder H; Brachvogel V; Lönze P; Weithmann KU
J Med Chem; 1999 Jun; 42(11):1908-20. PubMed ID: 10354399
[TBL] [Abstract][Full Text] [Related]
32. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
35. Inhibition and structure-activity studies of methionine hydroxamic acid derivatives with bacterial peptide deformylase.
Grant SK; Green BG; Kozarich JW
Bioorg Chem; 2001 Aug; 29(4):211-22. PubMed ID: 16256693
[TBL] [Abstract][Full Text] [Related]
36. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship analysis of the peptide deformylase inhibitor 5-bromo-1H-indole-3-acetohydroxamic acid.
Petit S; Duroc Y; Larue V; Giglione C; Léon C; Soulama C; Denis A; Dardel F; Meinnel T; Artaud I
ChemMedChem; 2009 Feb; 4(2):261-75. PubMed ID: 19053131
[TBL] [Abstract][Full Text] [Related]
38. Modeling the inhibition of peptide deformylase by hydroxamic acids: influence of the sulfur donor.
Galardon E; Giorgi M; Artaud I
Dalton Trans; 2007 Mar; (10):1047-52. PubMed ID: 17325780
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
